Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Celecoxib may be effective in preventing the further development of cancer.
Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or
deliver tumor-killing substances to them without harming normal cells. Combining trastuzumab
with celecoxib may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and trastuzumab in
treating women who have metastatic breast cancer that has not responded to previous
trastuzumab.